Please take the opportunity to express your concern related to this policy change. It will take only 1 minute to fill out the contact information on the right, and you may edit the message as you see fit. From there, the message will be sent to HCSC as well as federal and state healthcare policymakers. 

The issue: On April 15, 2025, HCSC, the parent company of the BlueCross BlueShield plans operating in 5 states (IL, TX, OK, MT and NM), began requiring prior authorization before certain respiratory treatments (Xolair, Nucala, Fasenra and Tezspire) can be administered in-office by a healthcare provider. If prior authorization is not granted, the patient must self-inject the drug at home.

We believe this policy will cause patient access challenges as well as potential safety issues. This restricts patient and provider choice, and we encourage you to voice your concerns with policymakers!